BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scaffaro LA, Stella SF, Alvares-Da-Silva MR, Kruel CDP. Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma. World J Hepatol 2015; 7(3): 628-632 [PMID: 25848487 DOI: 10.4254/wjh.v7.i3.628] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Jiao F, Long L, Ding S, Xie X, Jia L, Lu F. Complete genome sequencing and clinical analysis of intrahepatic hepatitis B virus cccDNA from HCC. Microb Pathog 2017;109:49-55. [PMID: 28478205 DOI: 10.1016/j.micpath.2017.04.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Pinato DJ, Howell J, Ramaswami R, Sharma R. Review article: delivering precision oncology in intermediate-stage liver cancer. Aliment Pharmacol Ther 2017;45:1514-23. [DOI: 10.1111/apt.14066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
3 Longo L, Rodrigues de Freitas LB, Santos D, Grivicich I, Álvares-da-Silva MR. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy. Am J Clin Oncol 2019;42:466-71. [PMID: 30913090 DOI: 10.1097/COC.0000000000000539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Chen HY, Kee KM, Lu SN, Wang JH, Chen CH, Hung CH, Yen YH, Kuo YH. Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization. J Formos Med Assoc 2021:S0929-6646(21)00315-6. [PMID: 34303584 DOI: 10.1016/j.jfma.2021.07.003] [Reference Citation Analysis]
5 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016; 6(1): 21-36 [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 15.0] [Reference Citation Analysis]
6 Scaffaro LA, Kruel CD, Stella SF, Gravina GL, Machado Filho G, Borges de Almeida CP, Pinto LC, Alvares-da-Silva MR, Kruel CR. Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres. Biomed Res Int 2015;2015:435120. [PMID: 26413523 DOI: 10.1155/2015/435120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Freitas LBR, Longo L, Santos D, Grivicich I, Álvares-da-Silva MR. Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population. World J Hepatol 2019; 11(9): 678-688 [PMID: 31602288 DOI: 10.4254/wjh.v11.i9.678] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
9 Lee S, Kim BK, Song K, Park JY, Ahn SH, Kim SU, Han KH, Kim DY; Korea Central Cancer Registry. Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. J Gastroenterol Hepatol. 2016;31:842-847. [PMID: 26513311 DOI: 10.1111/jgh.13218] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
10 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
11 Yi PS, Wang H, Li JS. Evolution and current status of the subclassification of intermediate hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(3): 85-92 [PMID: 32218891 DOI: 10.4240/wjgs.v12.i3.85] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer 2019;8:78-91. [PMID: 31019899 DOI: 10.1159/000489791] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
13 Wei W, Yang Z, Lu L, Li J, Lei Z, Wang K, Xia Y, Yan Z, Shen F. Long-term survival after partial hepatectomy for sub-stage patients with intermediate stage hepatocellular carcinoma. International Journal of Surgery 2018;56:256-63. [DOI: 10.1016/j.ijsu.2018.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Xu W, Rao Q, An Y, Li M, Xu G, Sang X, Lu X, Zhang Z, Mao Y. Proposal for subclassification to select patients for hepatectomy with intermediate hepatocellular carcinoma and Child-Pugh A liver function: A double-center study from China. Medicine (Baltimore). 2018;97:e11800. [PMID: 30095644 DOI: 10.1097/md.0000000000011800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]